| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6070011 | Journal of the American Academy of Dermatology | 2016 | 20 Pages |
Abstract
Secukinumab had a favorable safety profile, had no meaningful difference between the 300- and 150-mg doses and, in terms of safety, was comparable to etanercept over 52Â weeks in patients with moderate to severe plaque psoriasis.
Keywords
phase II studiesSAEMACENMSCsecukinumabANCIBDphase III studiesBCCTNFSCCMyocardial infarctionLong-term safetyinterleukinInflammatory bowel diseasePooled analysisAbsolute neutrophil countmajor adverse cardiovascular eventnonmelanoma skin cancerSOCadverse eventSerious adverse eventconfidence intervaltumor necrosis factorIncidence ratePsoriasisBasal cell carcinomaSquamous cell carcinomaSystem organ class
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Peter C.M. MD, PhD, Christopher E.M. MD, Kristian MD, PhD, Craig L. MD, Andrew MD, MBA, Tsen-Fang MD, Yankun PhD, Jiaqing MD, PhD, Charis MD, PhD, Todd RPh, PharmB, ACPR,